Assignee: Pfizer Products Inc.

Location: Groton, CT
No. of patents: 62

Number	Title	Issue Date
8183230	Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms The present invention is directed to pharmaceutical compositions containing a therapeutically effective amount of an Active Pharmaceutical Ingredient (“API”), a pharmaceutically acceptable cyclodextrin and a pharmaceutically acceptable preservative. The inventio...	05/22/2012
8114871	3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention...	02/14/2012
8008078	gene directing the ratio of B2:B1 avermectins The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. averm...	08/30/2011
7968584	Substituted arylpyrazoles This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthes...	06/28/2011
7858340	Polynucleotides and methods of directing the ratio of B2:B1 avermectins in host cells The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. averm...	12/28/2010
7803832	N-(1-arylpyrazol-4L)sulfonamides and their use as parasiticides The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such co...	09/28/2010
7687533	N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such co...	03/30/2010
7687507	Pyrrolo[2,3-d]pyrimidine compounds A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as imm...	03/30/2010
7638537	Pyrazole compounds as transforming growth factor (TGF) inhibitors Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming gro...	12/29/2009
7635702	Imidazole compounds as transforming growth factor (TGF) inhibitors Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming gr...	12/22/2009
7538134	Substituted arylpyrazoles This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthes...	05/26/2009
7417041	Imidazopyrimidines as transforming growth factor (TGF) inhibitors Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of tran...	08/26/2008
7378408	Methods of treatment and formulations of cephalosporin Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats. ...	05/27/2008
7378101	Vaccine for periodontal disease The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising...	05/27/2008
7361357	Safe mutant viral vaccines The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or...	04/22/2008
7354941	Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0):	04/08/2008
7297682	Diphosphate salt of a 4″—substituted-9-deoxo-9 A—AZA—homoerythromycin derivatives and its pharmaceutical composition This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-α-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideo...	11/20/2007
7259241	gene directing the ratio of B2:B1 avermectins The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. averm...	08/21/2007
7247628	Cannabinoid receptor ligands and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein. ...	07/24/2007
7214677	Benzamide, heteroarylamide and reverse amides The present invention relates to novel to P2X7 inhibitors of formula I and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, an...	05/08/2007
7199243	Piperidine compounds useful as PPAR activators PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol ...	04/03/2007
7183293	Ether derivatives useful as inhibitors of PDE4 isozymes This application is directed to compounds of the formula wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently —O— or —S(═O)t—, where t i...	02/27/2007
7173052	Resorcinol derivatives The present invention relates to certain resorcinol derivatives and their use as skin lightening agents. ...	02/06/2007
7153872	Imidazole compounds as transforming growth factor (TGF) inhibitors Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming gr...	12/26/2006
7151110	Pyrazole compounds as transforming growth factor (TGF) inhibitors Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming gro...	12/19/2006
7138406	Modulators of the glucocorticoid receptor The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1–R25 are as described in the speci...	11/21/2006
7067664	Corticotropin releasing factor antagonists Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 an...	06/27/2006
7030242	Selective inhibition of aggrecanase in osteoarthritis treatment This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate IC50s of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metallopro...	04/18/2006
7029683	derived gene and related hemolysin polypeptides, peptides and proteins and their uses The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In ...	04/18/2006
6979442	Stabilized protein compositions This invention relates to stabilized protein compositions, methods for preparing such stabilized protein compositions, dosage forms for administering such stabilized protein compositions to mammals and methods for preventing or treating infections in mammals by admi...	12/27/2005
6974575	Generation of type I/type II hybrid form of bovine viral diarrhea virus for use as vaccine The present invention provides genetically engineered type I/type II hybrid BVDV viruses. The hybrid viruses, as well as the hybrid viral genome, can be used in immunogenic compositions and vaccines for protecting cattle from BVDV infection. ...	12/13/2005
6974572	Non-anaphylactogenic IgE fusion proteins The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorde...	12/13/2005
6960609	1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands This invention relates to 1-diphenylmethyl-pyrazole derivatives of formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4 and R5 are de...	11/01/2005
6960604	Thyroid receptor ligands The invention provides thiazolidinedione, oxadiazolidinedione, and triazolone compounds of Formula (I) which compounds are thyroid receptor ligands. The invention further provides pharmaceutical compositions and kits com...	11/01/2005
6927219	N-alkyl-adamantyl triazinyl benzamide derivatives The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I: and to processs for their preparation, intermediates useful in their preparation, pharmaceutical compositions...	08/09/2005
6924310	Malonamic acids and derivatives thereof as thyroid receptor ligands The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias...	08/02/2005
6911206	Fusion proteins comprising carriers that can induce a dual immune response The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity...	06/28/2005
6897306	3-heterocyclylpropanohydroxamic acids Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by P...	05/24/2005
6887472	Anti-IgE vaccines The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the in...	05/03/2005
6858624	Aryl fused azapolycyclic compounds This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of...	02/22/2005

«First «Previous1 2 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Pfizer Products Inc.